Avaii Wealth Management LLC Sells 4,739 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Avaii Wealth Management LLC lowered its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 13.9% in the fourth quarter, Holdings Channel reports. The firm owned 29,283 shares of the biopharmaceutical company’s stock after selling 4,739 shares during the quarter. Avaii Wealth Management LLC’s holdings in TG Therapeutics were worth $500,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC lifted its stake in shares of TG Therapeutics by 164.5% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 1,367,400 shares of the biopharmaceutical company’s stock worth $11,431,000 after buying an additional 850,507 shares during the last quarter. 683 Capital Management LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth about $11,286,000. Charles Schwab Investment Management Inc. lifted its stake in shares of TG Therapeutics by 2.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,112,682 shares of the biopharmaceutical company’s stock worth $9,302,000 after buying an additional 31,872 shares during the last quarter. Rafferty Asset Management LLC lifted its stake in shares of TG Therapeutics by 183.2% during the 3rd quarter. Rafferty Asset Management LLC now owns 856,837 shares of the biopharmaceutical company’s stock worth $7,163,000 after buying an additional 554,309 shares during the last quarter. Finally, Jump Financial LLC lifted its stake in shares of TG Therapeutics by 342.2% during the 3rd quarter. Jump Financial LLC now owns 472,972 shares of the biopharmaceutical company’s stock worth $3,954,000 after buying an additional 366,012 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Price Performance

TGTX stock traded up $0.05 during mid-day trading on Monday, hitting $13.52. The stock had a trading volume of 1,298,201 shares, compared to its average volume of 4,077,931. The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62. TG Therapeutics, Inc. has a 52 week low of $6.46 and a 52 week high of $35.67. The firm has a market capitalization of $2.09 billion, a P/E ratio of 671.50 and a beta of 2.30. The firm has a fifty day simple moving average of $15.07 and a 200 day simple moving average of $14.22.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. The company had revenue of $43.97 million for the quarter, compared to analyst estimates of $40.06 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. During the same period in the previous year, the firm posted ($0.39) EPS. As a group, research analysts forecast that TG Therapeutics, Inc. will post -0.11 EPS for the current year.

Insider Activity at TG Therapeutics

In related news, Director Laurence N. Charney sold 22,000 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the sale, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 9.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

TGTX has been the subject of several analyst reports. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of TG Therapeutics in a research note on Thursday, April 18th. LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $39.00 price objective on shares of TG Therapeutics in a research note on Thursday, April 18th. StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $25.00 price objective on shares of TG Therapeutics in a research note on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, TG Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $29.00.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.